William Cance, MD, FACS

Surgeon-in-Chief
Chair, Department of Surgical Oncology
Roswell Park Cancer Institute
Co- Program Leader
Drug Discovery and Experimental Therapeutic Program
Cancer Center Support Grant
Professor and Academic Scholar
Department of Surgery
Member, Molecular and Cellular Biophysics and Biochemistry Program, Roswell Park Division
University of Buffalo, State University of New York

Profile

Areas of Expertise: 
GI Oncology
Endocrine Surgery
Pancreatic cancer
Thyroid cancer
Hyperparathyroidism and parathyroid surgery
Adrenal tumors
Biography: 

I am Chair of the Department of Surgical Oncology and Surgeon-In Chief and Board Certified in General Surgery. I treat patients with complex gastrointestinal cancers, with a special interest in pancreatic cancer. I also have a long standing interest in endocrine surgery, particularly in the diagnosis and treatment of thyroid and parathyroid diseases including thyroid cancer. One of my special interests is in the treatment of hyperparathyroidism patients by parathyroid surgery using the technique of MIRP (Minimal Invasive Radio-Guided Parathyroidectomy). This minimally invasive technique utilizes intra-operative nuclear mapping resulting in a small scar in the neck region. During the last several years this has become the preferred method of removing hyperfunctioning parathyroid glands.

I have an active translational science research laboratory that has been continuously funded by the NIH since 1992. Our work has centered on focal adhesion kinase (FAK) and its role in cancer. Our laboratory was the first to clone human FAK in the early 1990s and demonstrate its increased expression in invasive and metastatic cancers. We also were the first to show that inhibition of FAK expression induced apoptosis in tumor cells and we were pioneers in application of FAK antisense oligonucleotides in tumor treatment. We also demonstrated the importance of the scaffolding function of FAK in multiple pathways by discovering the interaction of FAK with Receptor Interaction Protein (RIP), tumor suppressor p53, and Vascular Endothelial Growth Factor Receptor 3. We have developed small molecule drugs that inhibit tumor growth through targeting these important protein-protein interactions and are actively pursuing them as novel therapeutic agents with pancreatic cancer as a major focus.

I am past President of the Society of Surgical Oncology, a member of the American Association of Endocrine Surgeons, American Association for Cancer Research, Society of University Surgeons, American Surgical Association, Society of Clinical Surgery, American Society of Clinical Oncology as well as a Fellow of the American College of Surgeons. In addition, I serve on the Editorial Board of the Annals of Surgical Oncology and the Journal of Clinical Oncology. I also serve on the Board of Scientific Counselors of the National Institute of Health.

Dr. Cance has been named as one of the Best Doctors in Western New York and Best Doctors in America.

Research

Research Interests: 
Development of anti-cancer drugs that target focal adhesion kinase (FAK)
Biology of focal adhesion kinase (FAK)
Role of FAK in preventing apoptosis
Other survival mechanisms of cancer cells

Background Information

Education and Training: 
MD - Duke U. School of Medicine, Durham, NC
Residency: 
Washington U. School of Medicine, St. Louis, MO
Board Certification: 
American Board of Surgery
Fellowships: 
Memorial Sloan Kettering Cancer Center, NY, NY

Cancer Talk Blog

May is National Skin Cancer Awareness Month, and with summer right around the corner, it’s important to remember that exposure to ultraviolet (UV) radiation from the sun can increase your risk of developing skin cancer.

Ask A Question

Do you have a cancer question you’d like RPCI cancer experts to address? Submit a topic for consideration.

close